Skip to main content
Clinical Trials/ACTRN12605000771651
ACTRN12605000771651
Terminated
Phase 4

A prospective comparison of early post-operative analgesia in Caesarean Section using bilateral ilio-inguinal block and sub-cutaneous morphine

Royal Women's Hospital0 sites120 target enrollmentNovember 30, 2005

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Royal Women's Hospital
Enrollment
120
Status
Terminated
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 30, 2005
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Royal Women's Hospital

Eligibility Criteria

Inclusion Criteria

  • Those scheduled to undergo elective lower uterine segment Caesarean Section for singleton term pregnancy (\>37 weeks gestation). Both multiparous and primparous women will be included.

Exclusion Criteria

  • Inability/unwillingness to give informed consent to participate\*Significantly limited English\*Height \<155cm or \>185cm (which may require adjustment of spinal dose)\*BMI \>35 (which may require adjustment of spinal dose)\*Conditions associated with a large uterus (macrosomia, polyhydramnios, multiple pregnancy) or small uterus (intra\-uterine growth retardation) which may require adjustment of spinal dose\*Classical Caesarean incision\*Anticipated complex surgery (eg. multiple previous laparotomies, including \>2 previous Caesarean Sections) or additional procedures planned (eg. tubal ligation) which may increase post\-operative pain and analgesic requirements\*Contra\-indication to spinal anaesthesia (such as lack of informed consent, local or generalised infection, coagulopathy, medical or obstetric conditions precluding spinal anaesthesia (eg. significant valvular heart disease, high grade placenta praevia)\*Allergy/sensitivity to local anaesthetic, paracetamol, fentanyl, morphine\*Allergy/sensitivity to non\-steroidal anti\-inflammatories (diclofenac), including such conditions as renal impairment, peptic ulcer disease, severe (NSAID\-sensitive) asthma\*Inability or unwillingness to use a PCA device.

Outcomes

Primary Outcomes

Not specified

Similar Trials